Back to Search
Start Over
Brentuximab Vedotin in Patients With CD30+ Mesothelioma
- Source :
- International Journal of Radiation Oncology*Biology*Physics. 90:S8
- Publication Year :
- 2014
- Publisher :
- Elsevier BV, 2014.
-
Abstract
- Conclusions: LDCT lung cancer screening is an uncommon practice at an academic medical center despite guideline recommendations. Furthermore, PCPs report ordering chest x-ray, a non-recommended screening test, more often than LDCT. Cost, potential harm, and patients’ lack of knowledge were the most commonly perceived barriers. However, PCP knowledge of LDCT guidelines was strongly associated with ordering LDCT. Educational interventions are critical to increasing LDCT screening and should specifically address effectiveness, guideline recommendations, cost, and potential harms. Author Disclosure: J. Lewis: None. W.J. Petty: None. J.A. Tooze: None. D.P. Miller: None. C. Chiles: None. A.A. Miller: None. K.E. Weaver: None.
- Subjects :
- Cancer Research
medicine.medical_specialty
Radiation
business.industry
Guideline
medicine.disease
Potential harm
Oncology
medicine
Radiology, Nuclear Medicine and imaging
Lack of knowledge
In patient
Mesothelioma
Educational interventions
business
Brentuximab vedotin
Intensive care medicine
Lung cancer screening
medicine.drug
Subjects
Details
- ISSN :
- 03603016
- Volume :
- 90
- Database :
- OpenAIRE
- Journal :
- International Journal of Radiation Oncology*Biology*Physics
- Accession number :
- edsair.doi...........4029cddbe6c04c449241bd7c9b73b4e2
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2014.08.035